The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 599-610

  Lesko, Samuel M ^a,b   Mitchell, Allen A ^b  

^a Northeast Regional Cancer Institute   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Blinding in detection bias minimization; Confounding by indication; Control treatment choice; Large, simple trials (LSTs); LST and follow up data collection; LST conducting logistics; Objective and easily measured outcomes; Randomized controlled trials (RCTs); Randomized controlled trials for pharmacoepidemiology studies

Indexed keywords

EID: 84889496391     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch39     Document Type: Chapter

References (42)

1. Mitchell AA, Lesko SM. When a randomized controlled trial is needed to assess drug safety: the case of pediatric ibuprofen. Drug Saf 1995; 13: 15-24.
2. Hasford J, Bussmann W-D, Delius W, Koepcke W, Lehmann K, Weber E. First dose hypotension with enalapril and prazosin in congestive heart failure. Int J Cardiol 1991; 31: 287-294.
3. Lesko S, Mitchell AA, Epstein MF, Louik C, Giacoia GP, Shapiro S. Heparin use as a risk factor for intraventricular hemorrhage in low-birth-weight infants. N Engl J Med 1986; 314: 1156-1160.
4. Malloy MH, Cutter GR. The association of heparin exposure with intraventricular hemorrhage among very low birth weight infants. J Perinatol 1995; 15: 185-191.
5. Chang GY, Leuder FL, DiMichele DM, Radkowski MA, McWilliams LJ, Jansen RD. Heparin and the risk of intraventricular hemorrhage in premature infants. J Pediatr 1997; 131: 362-366.
6. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in post-menopausal women. N Engl J Med 1976; 294: 1256-1259.
7. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985; 313: 1038-1043.
8. Byrd BF, Burch JC, Vaughn WK. The impact of long term estrogen support after hysterectomy. A report of 1016 cases. Ann Surg 1977; 185: 574-580.
9. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858-860.
10. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044-1049.
11. Women's Health Initiative (WHI) Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
13. Slone D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD. Drug evaluation after marketing. A policy perspective. Ann Intern Med 1979; 90: 257-261.
14. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994; 331: 394-398.
15. Francis T Jr, Korns R, Voight R, Boisen M, Hemphill F, Napier J et al. An evaluation of the 1954 poliomyelitis vaccine trials: summary report. Am J Public Health 1955; 45 (suppl): 1-50.
16. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397-402.
17. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto miocardico (GISSI). GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
18. GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
19. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; ii: 57-66.
20. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
21. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 399: 753-770.
22. ISIS-4 Collaborative Group Fourth International Study of Infarct Survival: Protocol for a large, simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. Am J Cardiol 1991; 68: 87D-100D.
23. Yusuf S. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. Herz 1993; 18(suppl): 444-448.
24. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancer in male smokers. N Engl J Med 1994; 330: 1029-1035.
25. Fisher B, Costantion JP, Wickerham DL, Redmond CK, Kavannah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
26. Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996; 19: 1225-1228.
27. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 1999; 354: 447-455.
28. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 2000; 342: 154-160.
29. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
30. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. The selenim and vitamin E cancer prevention trial. World J Urol 2003; 21: 21-27.
31. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A et al. Effects of combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
32. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
33. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
34. Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen: a practitioner-based randomized clinical trial. JAMA 1995; 273: 929-933.
35. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-420.
36. Hasford J. Drug risk assessment: a case for large trials with lean protocols. Pharmacoepidemiol Drug Saf 1994; 3: 321-317.
37. Gray R, Clarke M, Collins R, Peto R Making randomized trials larger: a simple solution? Eur J Surg Oncol 1995; 2: 137-139.
38. Hennekens CH, Buring JE. Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians' Health Study. Control Clin Trials 1989; 10: 142S-150S.
39. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst. 1999; 91(24): 2102-2106.
40. Santoro E, Nicolis E, Grazia Franzosi M. Telecommunications technology for the management of large scale clinical trials: the GISSI experience. Comput Methods Programs Biomed 1999; 60: 215-223.
41. O'Brien PC. Data and safety monitoring. In: Armitage P, Colton T, eds, Encyclopedia of Biostatistics. Chichester: John Wiley & Sons, 1998; pp. 1058-1066.
42. DeMets DL. Data and safety monitoring boards. In: Armitage P, Colton T, eds, Encyclopedia of Biostatistics. Chichester: John Wiley & Sons, 1998; pp. 1067-1071.